DK3820906T3 - Multispecifikke wnt-surrogatmolekyler og anvendelser deraf - Google Patents

Multispecifikke wnt-surrogatmolekyler og anvendelser deraf

Info

Publication number
DK3820906T3
DK3820906T3 DK19830971.8T DK19830971T DK3820906T3 DK 3820906 T3 DK3820906 T3 DK 3820906T3 DK 19830971 T DK19830971 T DK 19830971T DK 3820906 T3 DK3820906 T3 DK 3820906T3
Authority
DK
Denmark
Prior art keywords
multispecific
applications
wnt surrogate
surrogate molecules
molecules
Prior art date
Application number
DK19830971.8T
Other languages
English (en)
Inventor
Yang Li
Original Assignee
Surrozen Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surrozen Operating Inc filed Critical Surrozen Operating Inc
Application granted granted Critical
Publication of DK3820906T3 publication Critical patent/DK3820906T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK19830971.8T 2018-07-05 2019-07-05 Multispecifikke wnt-surrogatmolekyler og anvendelser deraf DK3820906T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862694339P 2018-07-05 2018-07-05
US201862782122P 2018-12-19 2018-12-19
US201962797772P 2019-01-28 2019-01-28
PCT/US2019/040687 WO2020010308A1 (en) 2018-07-05 2019-07-05 Multi-specific wnt surrogate molecules and uses thereof

Publications (1)

Publication Number Publication Date
DK3820906T3 true DK3820906T3 (da) 2025-12-15

Family

ID=69059929

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19830971.8T DK3820906T3 (da) 2018-07-05 2019-07-05 Multispecifikke wnt-surrogatmolekyler og anvendelser deraf

Country Status (10)

Country Link
US (1) US20210292422A1 (da)
EP (2) EP4733325A2 (da)
JP (2) JP2021529796A (da)
CN (2) CN120623353A (da)
AU (1) AU2019297522B2 (da)
CA (1) CA3104526A1 (da)
DK (1) DK3820906T3 (da)
ES (1) ES3058239T3 (da)
PL (1) PL3820906T3 (da)
WO (1) WO2020010308A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7305543B2 (ja) 2017-01-26 2023-07-10 スロゼン オペレーティング， インコーポレイテッド 組織特異的Ｗｎｔシグナル増強分子およびその使用
CN111699003B (zh) * 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
CN111655729B (zh) * 2017-12-19 2023-10-20 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
US20210032352A1 (en) * 2018-02-14 2021-02-04 Antera Therapeutics Inc. Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
AU2020300618A1 (en) * 2019-07-02 2022-01-27 Surrozen Operating, Inc. Monospecific anti-frizzled antibodies and methods of use
CN115427446A (zh) * 2020-02-24 2022-12-02 瑟罗泽恩奥普瑞汀公司 Wnt超级激动剂
TW202233656A (zh) 2020-11-16 2022-09-01 美商蘇羅森營運公司 肝特異性wnt訊號增強分子及其用途
WO2022130342A1 (en) * 2020-12-18 2022-06-23 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2023130055A2 (en) * 2021-12-31 2023-07-06 Surrozen Operating, Inc. Wnt receptor-specific compound and method relating thereto
AU2024279826A1 (en) * 2023-05-29 2026-01-08 Surrozen Operating, Inc. Wnt surrogate agents and methods for lacrimal gland regeneration

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
DE102004050620A1 (de) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoklonaler Antikörper gegen Frizzled-Rezeptoren
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
DE102005035568A1 (de) 2005-07-25 2007-02-01 M-Phasys Gmbh Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CN101573383B (zh) 2006-06-21 2015-05-13 肿瘤疗法科学股份有限公司 靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途
KR20100091170A (ko) * 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법
CA2705923A1 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
CN103002911B (zh) 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
ES2579909T3 (es) 2009-02-03 2016-08-17 Koninklijke Nederlandse Akademie Van Wetenschappen Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
AR080795A1 (es) 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP3033356B1 (en) 2013-08-14 2020-01-15 Sachdev Sidhu Antibodies against frizzled proteins and methods of use thereof
GB2519786A (en) * 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
US11142577B2 (en) * 2014-09-12 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University WNT signaling agonist molecules
WO2016205566A1 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
US10766962B2 (en) 2015-06-16 2020-09-08 The Regents Of The University Of California FZD7 specific antibodies and vaccines to treat cancer and control stem cell function
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
KR102802241B1 (ko) * 2015-12-04 2025-05-07 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
US10919968B2 (en) 2016-01-29 2021-02-16 Modmab Therapeutics Corporation Frizzled5 protein-binding agents
RU2767329C2 (ru) 2016-02-06 2022-03-17 Эпимаб Биотерапьютикс, Инк. Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
EP3732201A4 (en) * 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
US20210032352A1 (en) * 2018-02-14 2021-02-04 Antera Therapeutics Inc. Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof

Also Published As

Publication number Publication date
AU2019297522A1 (en) 2021-01-28
CN120623353A (zh) 2025-09-12
ES3058239T3 (en) 2026-03-09
CN112566940A (zh) 2021-03-26
CN112566940B (zh) 2025-06-13
EP3820906A1 (en) 2021-05-19
CA3104526A1 (en) 2020-01-09
AU2019297522B2 (en) 2026-04-23
JP2024001292A (ja) 2024-01-09
EP4733325A2 (en) 2026-04-29
US20210292422A1 (en) 2021-09-23
WO2020010308A1 (en) 2020-01-09
EP3820906A4 (en) 2022-04-20
JP2021529796A (ja) 2021-11-04
EP3820906B1 (en) 2025-10-15
PL3820906T3 (pl) 2026-04-13

Similar Documents

Publication Publication Date Title
DK3820906T3 (da) Multispecifikke wnt-surrogatmolekyler og anvendelser deraf
IL272463A (en) Nucleic acid molecules and uses thereof
EP3732201A4 (en) WNT SURROGATES AND THEIR USES
IL261942A (en) Bcma binding molecules and methods of use thereof
IL256416B (en) Multispecific antigen-binding molecules and uses thereof
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
DK3452089T3 (da) Bispecifikke bindingsproteiner og anvendelser deraf
DK3116909T3 (da) Antistofmolekyler til lag-3 og anvendelser deraf
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3601367T3 (da) Kimære molekyler og anvendelse deraf
PL3380522T3 (pl) Cząsteczki przeciwciał wobec april i ich zastosowania
DK3265575T3 (da) Cd20-bindende molekyler og anvendelser deraf
HUE054339T2 (hu) CD73-ra specifikus kötõmolekulák és alkalmazásaik
DK3922645T3 (da) Anti-pro/latent-myostatin-antistoffer og anvendelse heraf
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
DK3981792T3 (da) PD-1-bindende molekyler og fremgangsmåder til anvendelse deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3596125T3 (da) Anti-PAR2-antistoffer og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3402821T5 (da) Psma-bindende antistof og anvendelser deraf
DK3261720T3 (da) Antistoffer til tau og anvendelser deraf
DK3417058T3 (da) Sortase-modificerede molekyler og anvendelser deraf
IL261653A (en) Ilt7 binding molecules and methods of using the same